258 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
36
Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models.
University of Missouri St. Louis
49
Comparative binding energy analysis of HIV-1 protease inhibitors: incorporation of solvent effects and validation as a powerful tool in receptor-based drug design.
Universidad De Alcal£
19
Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.
Clarkson University
85
DoMCoSAR: a novel approach for establishing the docking mode that is consistent with the structure-activity relationship. Application to HIV-1 protease inhibitors and VEGF receptor tyrosine kinase inhibitors.
Eli Lilly
174
3D-quantitative structure-activity relationships of human immunodeficiency virus type-1 proteinase inhibitors: comparative molecular field analysis of 2-heterosubstituted statine derivatives-implications for the design of novel inhibitors.
Sandoz Forschungsinstitut Ges.M.B.H.
29
Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes.
Washington University
75
Three-dimensional QSAR of human immunodeficiency virus (I) protease inhibitors. 1. A CoMFA study employing experimentally-determined alignment rules.
Washington University
51
Six-membered cyclic ureas as HIV-1 protease inhibitors: a QSAR study based on CODESSA PRO approach. Quantitative structure-activity relationships.
University of Florida
23
Synthesis and antiviral activity of a novel class of HIV-1 protease inhibitors containing a heterocyclic P1-P2 amide bond isostere
TBA
3
Stereocontrolled synthesis and biological activity of two diastereoisomers of the potent HIV-1 protease inhibitor saquinavir.
Sapienza University of Rome
2
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
Glaxosmithkline
22
Microwave-accelerated synthesis of P1'-extended HIV-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold.
Uppsala University
43
Development of low molecular weight HIV-1 protease dimerization inhibitors.
Purdue University
27
Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.
Uppsala University
13
A unidirectional crosslinking strategy for HIV-1 protease dimerization inhibitors.
Purdue University
2
A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution.
Academy of Sciences of The Czech Republic
30
Countering cooperative effects in protease inhibitors using constrained beta-strand-mimicking templates in focused combinatorial libraries.
The University of Queensland
7
Dimerization inhibitors of HIV-1 protease based on a bicyclic guanidinium subunit.
Universidad Aut£Noma De Madrid
55
Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.
Uppsala University
18
Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
Universita' Degli Studi Di Salerno
37
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
Pfizer
8
Conformational selection of inhibitors and substrates by proteolytic enzymes: implications for drug design and polypeptide processing.
University of Queensland
6
Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.
The University of Queensland
31
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.
Merck Research Laboratories
14
Modeling of the inhibition of retroviral integrases by styrylquinoline derivatives.
Cnrs Umr 8532
3
Optimizing the binding of fullerene inhibitors of the HIV-1 protease through predicted increases in hydrophobic desolvation.
University of California
4
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Agouron Pharmaceuticals
12
An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.
University of Pennsylvania
38
Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.
National Cancer Institute-Bethesda
35
Application of the three-dimensional structures of protein target molecules in structure-based drug design.
Abbott Laboratories
7
Evaluation of a vitamin-cloaking strategy for oligopeptide therapeutics: biotinylated HIV-1 protease inhibitors.
Upjohn Laboratories
22
Inhibitors of the protease from human immunodeficiency virus: synthesis, enzyme inhibition, and antiviral activity of a series of compounds containing the dihydroxyethylene transition-state isostere.
Upjohn Laboratories
11
Peptidomimetic HIV protease inhibitors: phosphate prodrugs with improved biological activities.
Upjohn
4
Multiple copy simultaneous search and construction of ligands in binding sites: application to inhibitors of HIV-1 aspartic proteinase.
Harvard University
24
Intriguing structure-activity relations underlie the potent inhibition of HIV protease by norstatine-based peptides.
Syntex Research
27
New hydroxyethylamine HIV protease inhibitors that suppress viral replication.
University of Wisconsin-Madison
13
Specific inhibition of HIV-1 protease by boronated porphyrins.
University of California
16
Inhibitors of the protease from human immunodeficiency virus: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity.
Upjohn
28
HIV protease: a novel chemotherapeutic target for AIDS.
Merck Sharp and Dohme Research Laboratories
5
Examination of HIV-1 protease secondary structure specificity using conformationally constrained inhibitors.
University of Illinois
13
Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere.
Roche Products
8
Structure-based design and synthesis of HIV-1 protease inhibitors employing beta-D-mannopyranoside scaffolds.
University College Dublin
25
Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
Dupont Pharmaceuticals
13
Simplified catechin-gallate inhibitors of HIV-1 reverse transcriptase.
University of Toledo
2
Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates.
Kyoto Pharmaceutical University
4
The sulfonimidamide as a novel transition state analog for aspartic acid and metallo proteases.
The University of Kansas
10
Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors.
University of Illinois At Chicago
12
Restricting the flexibility of crosslinked, interfacial peptide inhibitors of HIV-1 protease.
Purdue University
35
Structure-activity relationships for macrocyclic peptidomimetic inhibitors of HIV-1 protease
TBA
18
Peptidomimetic inhibitors of human immunodeficiency virus protease (HIV-PR): Design, enzyme binding and selectivity, antiviral efficacy, and cell permeability properties
TBA
9
Synthesis of irreversible HIV-1 protease inhibitors containing sulfonamide and sulfone as amide bond isosteres
TBA
3
Cyclic urea HIV protease inhibitors containing alkynyl- and alkenyl-tethered heterocycles in the P2 region
TBA
5
Design, synthesis, and characterization of dipeptide isostere containing cis-epoxide for the irreversible inactivation of HIV protease
TBA
7
β-Methanesulfonyl-L-valine as a novel, unnatural amino acid surrogate for P2 in the design of HIV protease inhibitors.
TBA
18
(Hydroxyethyl) sulfonamide HIV-1 Protease inhibitors: Identification of the 2-methylbenzoyl moiety at P-2
TBA
6
Synthesis and activity of conformationally-constrained macrocyclic norstatine-based inhibitors of HIV protease
TBA
37
Nonpeptidic HIV protease inhibitors: 3-(S-benzyl substituted)-4-hydroxy-6-(phenyl substituted)-2H-pyran-2-one with an inverse mode of binding
TBA
32
A topliss tree analysis of the HIV-protease inhibitory activity of 6-phenyl-4-hydroxy-pyran-2-ones
TBA
14
Aminodiol HIV protease inhibitors. 2. 1,1-Dimethyl-2-hydroxyethyl carbamate derivatives with enhanced potency
TBA
7
Ly316340: A potent HIV-1 protease inhibitor containing a high affinity octahydrothienopyridine hydroxyethylamine isostere
TBA
30
Evaluation of substituted benzamides as P2 ligands for symmetry-based inhibitors of HIV protease
TBA
15
Structure-based design of achiral anthranilamides as P2/P2′ surrogates for symmetry-based HIV protease inhibitors: design, synthesis, X-ray structure, enzyme inhibition and antiviral activity
TBA
13
Thiophene derivatives as extremely high affinity P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors
TBA
9
Substituted alkylpyridines as P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors: Improved pharmacokinetic profiles
TBA
7
Symmetry-based HIV Protease inhibitors: rational design of 2-methylbenzamides as novel P2/P2′ ligands
TBA
14
Cyclic sulfone-3-carboxamides as novel P2-ligands for Ro 31-8959 based HIV-1 protease inhibitors
TBA
2
Synthesis of C2-symmetric inhibitors of the HIV-1 protease, with N,N′-substituted ethylenediamide and ethylenediamine linkers.
TBA
7
Design, structure activity and x-ray crystallographic studies of pseudosymmetrical nonpeptidyl HIV-1 protease inhibitors
TBA
13
Novel, extended transition state mimic in HIV-1 protease inhibitors with peripheral C-2-symmetry
TBA
13
Synthesis and evaluation of pyridyl analogs of L-735,524: Potent HIV-1 protease inhibitors
TBA
14
Beneficial replacement of the P1 phenylalanine side chain in HIV-1 protease inhibitors of the difluorostatone type
TBA
23
A new hydroxyethylamine class of HIV-1 protease inhibitors with high antiviral potency and oral bioavailability
TBA
19
Design, synthesis, and activity of conformationally-constrained macrocyclic peptide-based inhibitors of HIV protease
TBA
13
Novel conformationally constrained HIV-1 protease inhibitors: rational design, enzyme inhibition, and X-ray structure of an enzyme-inhibtor complex
TBA
15
Increased antiviral activity of HIV protease inhibitors of the difluorostatone type bearing (R)-valinol derivatives as novel c-termini
TBA
6
Inhibition of human immunodeficiency virus-1 protease by a C2-symmetrical phosphinic acid amide
TBA
21
Difunctional enols of N-protected amino acids as low molecular weight and novel inhibitors of HIV-1 protease.
TBA
10
Novel dimeric penicillin derived inhibitors of HIV-1 proteinase: interaction with the catalytic aspartates
TBA
2
On-Resin Assembly of Macrocyclic Inhibitors of Cryptococcus neoformans May1: A Pathway to Potent Antifungal Agents.
Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
9
Potent HIV‑1 protease inhibitors containing oxabicyclo octanol-derived P2-ligands: Design, synthesis, and X‑ray structural studies of inhibitor-HIV-1 protease complexes.
Purdue University
4
Current status of the small molecule anti-HIV drugs in the pipeline or recently approved.
University of Rwanda
7
Natural products as potential lead compounds to develop new antiviral drugs over the past decade.
Nanjing University of Chinese Medicine
37
Unveiling sultam in drug discovery: spotlight on the underexplored scaffold.
Monash University
21
Click chemistry-aided drug discovery: A retrospective and prospective outlook.
Hangzhou Normal University
28
Structure based design and evaluation of benzoheterocycle derivatives as potential dual HIV-1 protease and reverse transcriptase inhibitors.
Peking Union Medical College
22
Indole-containing pharmaceuticals: targets, pharmacological activities, and SAR studies.
Tianjin University
33
Rational design, synthesis and biological evaluation of novel HIV-1 protease inhibitors containing 2-phenylacetamide derivatives as P2 ligands with potent activity against DRV-Resistant HIV-1 variants.
Xuzhou Medical University
8
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China.
Qufu Normal University
17
Exploration of imatinib and nilotinib-derived templates as the P2-Ligand for HIV-1 protease inhibitors: Design, synthesis, protein X-ray structural studies, and biological evaluation.
Purdue University
33
Design, synthesis, and biological evaluation of novel HIV-1 protease inhibitors containing pyrrolidine-derived P2 ligands to combat drug-resistant variant.
Chinese Academy of Medical Science and Peking Union Medical College
3
Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties.
Biocon Bristol-Myers Squibb R&D Centre
16
Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.
The Scripps Research Institute
15
Evaluation of darunavir-derived HIV-1 protease inhibitors incorporating P2' amide-derivatives: Synthesis, biological evaluation and structural studies.
Purdue University
40
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.
Purdue University
57
Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.
Bristol Myers Squibb
4
HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.
Academy of Sciences of The Czech Republic
8
Recent advances in steroid amino acid conjugates: Old scaffolds with new dimensions.
Panjab University
26
Pseudoprolines as stereoelectronically tunable proline isosteres.
Bristol Myers Squibb
3
Inhibition of HIV-1 Protease by a Boronic Acid with High Oxidative Stability.
Massachusetts Institute of Technology
4
Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization.
Paris-Sud University
3
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
Shionogi
27
Design, synthesis and biological evaluation of protease inhibitors containing morpholine cores with remarkable potency against both HIV-1 subtypes B and C.
Peking Union Medical College
27
A kind of HIV-1 protease inhibitors containing phenols with antiviral activity against DRV-resistant variants.
Peking Union Medical College
10
A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
Uppsala University
5
Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.
Abbott Laboratories
5
Design, synthesis, and biological evaluation of novel 4-hydroxypyrone derivatives as HIV-1 protease inhibitors.
Peking University
3
Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.
University of Debrecen
16
Highly Potent and Oral Macrocyclic Peptides as a HIV-1 Protease Inhibitor: mRNA Display-Derived Hit-to-Lead Optimization.
Shionogi
3
New 2-bromomethyl-8-substituted-benzo[c]chromen-6-ones. Synthesis and biological properties.
University of The Mediterranean
15
New constrained"molecular tongs" designed to dissociate HIV-1 protease dimer.
Paris-Sud University
37
Efficient evaluation of binding free energy using continuum electrostatics solvation.
University of ZüRich
2
Facile incorporation of urea pseudopeptides into protease substrate analogue inhibitors.
Purdue University
1
Re-emerging Aspartic Protease Targets: Examining
Institute of Organic Chemistry and Biochemistry of The Czech Academy of Sciences
4
Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.
Abbott Laboratories
22
Novel nonpeptidic inhibitors of HIV-1 protease obtained via a new multicomponent chemistry strategy.
Morphochem
3
BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease.
Vertex Pharmaceuticals
22
Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants.
Peking Union Medical College
44
Design and biological evaluation of cinnamic and phenylpropionic amide derivatives as novel dual inhibitors of HIV-1 protease and reverse transcriptase.
Peking Union Medical College
27
l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance.
The University of Georgia
13
Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.
Merck Research Laboratories
5
Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.
Kyoto University
38
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.
University of Nebraska Medical Center
10
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
Bristol Myers Squibb
8
Design, Synthesis, and X-ray Studies of Potent HIV-1 Protease Inhibitors with P2-Carboxamide Functionalities.
Purdue University
8
Design and synthesis of pseudo-symmetric HIV protease inhibitors containing a novel hydroxymethylcarbonyl (HMC)-hydrazide isostere.
Kyoto Pharmaceutical University
4
Combinatorial library of indinavir analogues: replacement for the aminoindanol at P2'.
Merck Research Laboratories
14
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.
Merck Research Laboratories
5
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.
Merck Research Laboratories
5
Synthesis and antiviral activity of new anti-HIV amprenavir bioisosteres.
University of The Mediterranean
1
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
Pfizer
35
Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase.
Peking Union Medical College
18
A combinatorial library of indinavir analogues and its in vitro and in vivo studies.
Merck Research Laboratories
36
Elucidating the inhibiting mode of AHPBA derivatives against HIV-1 protease and building predictive 3D-QSAR models.
Chinese Academy of Sciences
15
Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.
University of Massachusetts Medical School
29
Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1' ligand to enhance binding with S1' subsite.
Peking Union Medical College
3
Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir).
Abbott Laboratories
25
Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants.
Peking Union Medical College
29
Design, synthesis and biological evaluation of HIV-1 protease inhibitors with morpholine derivatives as P2 ligands in combination with cyclopropyl as P1' ligand.
Jinzhou Medical University
12
Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3' residue.
The Scripps Research Institute
7
6-Hydroxy-1,3-dioxin-4-ones as non-peptidic HIV protease inhibitors.
Institute of Science & Technology
10
Use of proline bioisosteres in potential HIV protease inhibitors: phenylalanine-2-thiophenoxy-3-pyrrolidinone: synthesis and anti-HIV evaluation.
Université
3
Combinatorial diversification of indinavir: in vivo mixture dosing of an HIV protease inhibitor library.
Merck Research Laboratories
1
'Double-Drugs'--a new class of prodrug form of an HIV protease inhibitor conjugated with a reverse transcriptase inhibitor by a spontaneously cleavable linker.
Kyoto Pharmaceutical University
14
A new class of HIV-1 integrase inhibitors: the 3,3,3', 3'-tetramethyl-1,1'-spirobi(indan)-5,5',6,6'-tetrol family.
University of California
6
Synthesis and biological evaluation of the first N-alkyl cage dimeric 4-aryl-1,4-dihydropyridines as novel nonpeptidic HIV-1 protease inhibitors.
Martin-Luther-University Halle-Wittenberg
11
Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents.
Dupont Pharmaceuticals
7
Inhibitors of the C(2)-symmetric HIV-1 protease: nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2' side chains.
Uppsala University
11
Increased antiviral activity of cyclic urea HIV protease inhibitors by modifying the P1/P1' substituents.
Dupont Pharmaceuticals
14
4-hydroxy-5,6-dihydro-2H-pyran-2-ones.3. Bicyclic and hetero-aromatic ring systems as 3-position scaffolds to bind to S1' and S2' of the HIV-1 protease enzyme.
Warner-Lambert
31
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing achiral 3-(4-amino/carboxamide-2-t-butyl,5-methylphenyl thio) moiety: antiviral activities and pharmacokinetic properties.
Warner-Lambert
3
Structure-based design of diaminopyranosides as a novel inhibitor core unit of HIV proteases.
Biomolecular Engineering Research Institute
1
A new class of anti-HIV agents: synthesis and activity of conjugates of HIV protease inhibitors with a reverse transcriptase inhibitor.
Kyoto Pharmaceutical University
9
Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization.
Université
8
Design and synthesis of novel conformationally restricted HIV protease inhibitors.
Vertex Pharmaceuticals
32
Design, synthesis, and conformational analysis of a novel series of HIV protease inhibitors.
Vertex Pharmaceuticals
27
Unsymmetric nonpeptidic HIV protease inhibitors containing anthranilamide as a P2' ligand.
Aids Drug Screening and Development Laboratory
118
Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
Lindsley F. Kimball Research Institute
3
NMR and topochemical studies of peptidomimetic HIV-I protease inhibitors containing a cis-epoxide amide isostere.
Biotech Research Institute
1
Synthesis and anti-HIV activities of symmetrical N1,N3-dibenzyl-2-hydroxy-propane derivatives.
Université
8
Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.
Pharmacia & Upjohn
17
The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
Dupont Pharmaceuticals
9
Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups.
Dupont Pharmaceuticals
16
Novel HIV-protease inhibitors containing beta-hydroxyether and -thioether dipeptide isostere surrogates: modification of the P3 ligand.
Schering-Plough Research Institute
12
Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
LinköPing University
52
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
Dupont Pharmaceuticals
26
Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
Dupont Pharmaceuticals
7
Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors.
National Cancer Institute-Frederick
12
Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.
Abbott Laboratories
24
Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
Dupont Pharmaceuticals
17
Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
Dupont Pharmaceuticals
23
Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
Pharmacia & Upjohn
42
HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
Dupont Pharmaceuticals
22
Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: exploring the impact of ring size on structure-activity relationships.
Pharmacia and Upjohn
3
New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors.
Gilead Sciences
26
Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity.
Universitá
9
Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents.
University of North Carolina at Chapel Hill
3
Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers.
Medichem Research
46
Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol.
Abbott Laboratories
5
A novel constrained reduced-amide inhibitor of HIV-1 protease derived from the sequential incorporation of gamma-turn mimetics into a model substrate.
Smithkline Beecham Pharmaceuticals
7
A series of penicillin-derived C2-symmetric inhibitors of HIV-1 proteinase: structural and modeling studies.
Glaxo Group Research
6
Calculation of relative differences in the binding free energies of HIV1 protease inhibitors: a thermodynamic cycle perturbation approach.
Agouron Pharmaceuticals
9
Haloperidol-based irreversible inhibitors of the HIV-1 and HIV-2 proteases.
University of California
3
Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran.
Merck Research Laboratories
33
Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors: heterocyclic ring systems containing P1' and P2' substituents.
Glaxo Research and Development
2
Design, synthesis, and conformational analysis of a novel macrocyclic HIV-protease inhibitor.
Marion Merrell Dow Research Institute
19
L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.
Merck Research Laboratories
11
Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere.
Smithkline Beecham Pharmaceuticals
15
Inhibitors of HIV-1 protease containing the novel and potent (R)-(hydroxyethyl)sulfonamide isostere.
Searle Discovery Research
6
Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase.
Purdue University
49
A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site.
Merck Research Laboratories
2
A check on rational drug design: crystal structure of a complex of human immunodeficiency virus type 1 protease with a novel gamma-turn mimetic inhibitor.
Smithkline Beecham Pharmaceuticals
8
Synthetic chemical diversity: solid phase synthesis of libraries of C2 symmetric inhibitors of HIV protease containing diamino diol and diamino alcohol cores.
Abbott Laboratories
2
Anti-AIDS (acquired immune deficiency syndrome) agents. 17. New brominated hexahydroxybiphenyl derivatives as potent anti-HIV agents.
University of North Carolina at Chapel Hill
5
Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.
Tosoh
6
Synthesis of naphthalenesulfonic acid small molecules as selective inhibitors of the DNA polymerase and ribonuclease H activities of HIV-1 reverse transcriptase.
College of Pharmacy
31
Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure.
Upjohn Laboratories
60
Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor- and receptor-based properties.
University of Missouri-St. Louis
43
SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.
Harvard University
17
Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease.
University of Wisconsin-Madison
10
Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes.
University of Wisconsin-Madison
16
A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity.
Merck Research Laboratories
11
Penicillin derived C2-symmetric dimers as novel inhibitors of HIV-1 proteinase.
Glaxo Group Research
